The Greatest FDA Advisory Committees Of All Time Part IV: Neurology Lays Claim To The Crown
We look back at another of the greatest FDA advisory committees of the last 20 years. This time: the nearly 12-hour meeting in 2016 on Sarepta’s eteplirsen for Duchenne muscular dystrophy.
You may also be interested in...
Senators write US FDA commissioner seeking ‘fulsome public input’ at panel review of DMD gene therapy. The open public hearing is scheduled to run an average amount for a neurodegenerative advisory committee – but less than half the time of the OPH at the last Sarepta meeting.
Review documents show eight center director briefings during the IND phase and seven after NDA submission of Sarepta's DMD drug.
CDER Director Woodcock grants accelerated approval after FDA Commissioner Califf refuses to overturn her finding that the drug's effect on dystrophin is reasonably likely to predict clinical benefit in Duchenne muscular dystrophy.